AU2003220585A1 - Solubilization of weak bases - Google Patents

Solubilization of weak bases Download PDF

Info

Publication number
AU2003220585A1
AU2003220585A1 AU2003220585A AU2003220585A AU2003220585A1 AU 2003220585 A1 AU2003220585 A1 AU 2003220585A1 AU 2003220585 A AU2003220585 A AU 2003220585A AU 2003220585 A AU2003220585 A AU 2003220585A AU 2003220585 A1 AU2003220585 A1 AU 2003220585A1
Authority
AU
Australia
Prior art keywords
composition
carbon atoms
compound
pharmaceutical composition
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003220585A
Other languages
English (en)
Inventor
Samuel H Yalkowsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Arizona
Original Assignee
University of Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Arizona filed Critical University of Arizona
Publication of AU2003220585A1 publication Critical patent/AU2003220585A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003220585A 2002-03-26 2003-03-26 Solubilization of weak bases Abandoned AU2003220585A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36868402P 2002-03-26 2002-03-26
US60/368,684 2002-03-26
PCT/US2003/009668 WO2003082273A1 (en) 2002-03-26 2003-03-26 Solubilization of weak bases

Publications (1)

Publication Number Publication Date
AU2003220585A1 true AU2003220585A1 (en) 2003-10-13

Family

ID=28675527

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003220585A Abandoned AU2003220585A1 (en) 2002-03-26 2003-03-26 Solubilization of weak bases

Country Status (7)

Country Link
US (1) US7022712B2 (enExample)
EP (1) EP1487439A1 (enExample)
JP (1) JP2005521712A (enExample)
AU (1) AU2003220585A1 (enExample)
CA (1) CA2478470A1 (enExample)
MX (1) MXPA04009201A (enExample)
WO (1) WO2003082273A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002239395A1 (en) * 2000-11-01 2002-06-03 The Procter And Gamble Company Hiv treatment with benzimidazoles
US20080132419A1 (en) * 2006-10-04 2008-06-05 Nair Rodriguez-Hornedo Dissolution and precipitation of cocrystals with ionizable components
US9566233B2 (en) 2013-11-14 2017-02-14 Insys Development Company, Inc. Ondansetron sublingual spray formulation
JP6797795B2 (ja) * 2014-11-06 2020-12-09 クセリア ファーマシューティカルズ エーピーエスＸｅｌｌｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ ＡｐＳ グリコペプチド組成物
US10172833B2 (en) 2015-08-11 2019-01-08 Insys Development Company, Inc. Sublingual ondansetron spray

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3738995A (en) * 1971-05-14 1973-06-12 Du Pont Solvent process for the preparation of 1 - carbamoyl-substituted 2 - benzimidazolecarbamates
DE2340741A1 (de) * 1973-08-11 1975-02-20 Basf Ag Fungizid
DE2952239A1 (de) * 1979-12-22 1981-07-02 Celamerck Gmbh & Co Kg, 6507 Ingelheim Fungizide mischungen
FI68498C (fi) * 1981-06-25 1985-10-10 Web Berlin Chemie Blandning foer bekaempning av fytopatogeniska svampar och bakterier
DE3323024A1 (de) * 1983-06-25 1985-01-03 Hoechst Ag, 6230 Frankfurt Verfahren zur verminderung von nebenproduktanteilen bei der herstellung von carbendazim
GB8521082D0 (en) * 1985-08-22 1985-09-25 Ici Plc Fungicides
GB8629360D0 (en) * 1986-12-09 1987-01-21 Sandoz Ltd Fungicides
US5591744A (en) * 1987-04-16 1997-01-07 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic compounds
US5198444A (en) * 1987-04-17 1993-03-30 Imperial Chemical Industries Plc Methyl α-(2-substituted)pyrid-3-yl-β-methoxyacrylates, compositions containing them and their use as fungicides
HU202728B (en) * 1988-01-14 1991-04-29 Eszakmagyar Vegyimuevek Synergetic fungicide and acaricide compositions containing two or three active components
DE4142731A1 (de) * 1991-12-21 1993-06-24 Hoechst Ag Biozide polymerisate und polymerisatdispersionen, verfahren zu ihrer herstellung und ihre verwendung
DE4242389C2 (de) * 1992-12-08 1995-09-21 Schuelke & Mayr Gmbh Wäßrige Dispersion mit fungizider und algistatischer Wirkung
NZ305784A (en) 1995-04-12 2001-03-30 Procter & Gamble Benzimidazole containing medicaments for treating cancers, tumors and viral infections
US6262093B1 (en) * 1995-04-12 2001-07-17 The Proctor & Gamble Company Methods of treating cancer with benzimidazoles
ZA962879B (en) * 1995-04-12 1997-03-17 Procter & Gamble A pharmaceutical composition for inhibiting the growth of viruses and cancers
US5629341A (en) * 1995-04-12 1997-05-13 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US6479526B1 (en) * 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US6265427B1 (en) * 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
GB9725445D0 (en) * 1997-12-01 1998-01-28 Ciba Geigy Ag Organic compounds
US6506783B1 (en) * 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
AU2155399A (en) * 1997-12-01 1999-06-16 Novartis Ag Fungicidal combinations comprising quinazolinone
JP4424763B2 (ja) * 1998-04-09 2010-03-03 サントリーホールディングス株式会社 超臨界水処理による芳香族化合物の製造方法
US6245789B1 (en) * 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
AU763431B2 (en) * 1999-03-31 2003-07-24 Uaf Technologies And Research Llc Viral treatment
US6197805B1 (en) * 1999-05-27 2001-03-06 Troy Technology Corporation, Inc. Broad spectrum antimicrobial mixtures
US6423734B1 (en) 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
US6228400B1 (en) 1999-09-28 2001-05-08 Carlsbad Technology, Inc. Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
US6384049B1 (en) 2000-05-25 2002-05-07 The Procter & Gamble Company Cancer treatment
US6608096B1 (en) * 2000-09-26 2003-08-19 University Of Arizona Foundation Compounds and methods for use thereof in the treatment of cancer or viral infections
US6407105B1 (en) * 2000-09-26 2002-06-18 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6462062B1 (en) * 2000-09-26 2002-10-08 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
JP2004509949A (ja) 2000-09-26 2004-04-02 ザ　ユニバーシティ　オブ　アリゾナ　ファウンデーション 化合物および癌またはウイルス性感染症治療におけるその使用方法
US6380232B1 (en) * 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
AU2002239395A1 (en) 2000-11-01 2002-06-03 The Procter And Gamble Company Hiv treatment with benzimidazoles

Also Published As

Publication number Publication date
WO2003082273A1 (en) 2003-10-09
US20030195225A1 (en) 2003-10-16
US7022712B2 (en) 2006-04-04
JP2005521712A (ja) 2005-07-21
EP1487439A1 (en) 2004-12-22
MXPA04009201A (es) 2005-09-08
CA2478470A1 (en) 2003-10-09

Similar Documents

Publication Publication Date Title
KR100708360B1 (ko) 라스-파르네실트란스퍼라제 억제제와술포부틸에테르-7-β-시클로덱스트린 또는2-히드록시프로필-β-시클로덱스트린과의 착물 및 방법
US5571534A (en) Drug formulations for parenteral use
US6319943B1 (en) Oral formulation for paclitaxel
CA2414064C (en) Clear aqueous anaesthetic composition
AU2002306329B2 (en) Aqueous cilostazol preparation for injection
WO2017127835A2 (en) Aqueous formulations and methods of preparation and use thereof
BR122020021551B1 (pt) Composição farmacêutica antimicrobiana e seu uso
KR20150022839A (ko) 아프레피탄트 주사용 제제
JP2008542260A (ja) 新規の注射可能組成物及びその調製方法
US20100048645A1 (en) Solubilizing of metronidazole
EP1214078B1 (en) Formulations for parenteral use of estramustine phosphate and amino acids
US7022712B2 (en) Solubilization of weak bases
JP4275394B2 (ja) 注射用シロスタゾール水性製剤
US7157446B2 (en) Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
ITMI20001984A1 (it) Uso dell'arginina nella preparazione di un medicamento per la preparazione e trattamento degli effetti collaterali associati alla somministr
ITMI991998A1 (it) Formulazioni di estramustina fosfato ed albumina per uso parenterale
KR20140017516A (ko) 피리디늄 및 퀴놀리늄 유도체의 약학 조성물

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application